ChimerixCMRX
Market Cap: $79.8M
About: Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Employees: 72
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2.27% less ownership
Funds ownership: 43.51% [Q1] → 41.24% (-2.27%) [Q2]
6% less funds holding
Funds holding: 77 [Q1] → 72 (-5) [Q2]
21% less capital invested
Capital invested by funds: $41.2M [Q1] → $32.4M (-$8.77M) [Q2]
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
65% less call options, than puts
Call options by funds: $63K | Put options by funds: $178K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Edward White 28% 1-year accuracy 34 / 121 met price target | 1,136%upside $11 | Buy Reiterated | 14 Aug 2024 |